When patients sit down in my exam room to talk about stem cells, platelet‑rich plasma, or “regrowing cartilage,” they usually want two things: honest numbers and a road map. They have already seen the marketing. They want to know what actually works, for whom, and at what cost.
Regenerative medicine sits in an interesting place. It is not science fiction anymore, but it is also not the miracle cure many ads suggest. The reality in clinics is far more nuanced, and that nuance matters when you are deciding whether to spend thousands of dollars on a treatment your insurance may not cover.
This article walks through what I and many colleagues see day to day: who benefits, who does not, what the success rates look like by condition, and how to think about cost, risk, and expectations in a grounded way.
What is a regenerative medicine doctor, really?
Patients often ask, sometimes a bit skeptically, “What is a regenerative medicine doctor, and how is that different from a regular orthopedist or sports med doctor?”
In practice, most “regenerative medicine doctors” are physicians who trained first in another specialty, then added advanced skills in biologic treatments. Common backgrounds include orthopedic surgery, sports medicine, physical medicine and rehabilitation (PM&R), pain management, rheumatology, and sometimes dermatology or plastic surgery for aesthetic and wound care work.
Instead of relying solely on structural fixes like joint replacements or fusion surgery, these physicians try to harness the body’s own repair mechanisms. That might mean concentrating platelets from your blood, using bone marrow or fat tissue to harvest stem and progenitor cells, or placing biologic scaffolds that help damaged tissue remodel rather than simply scar.
In a typical clinic week, a regenerative medicine doctor might:
- Inject platelet‑rich plasma (PRP) into a degenerative tendon or arthritic knee Use bone marrow concentrate to treat focal cartilage loss or severe joint degeneration Guide injections with ultrasound or fluoroscopy to target spinal facet joints or discs Manage rehab plans that combine biologics with physical therapy and strength work
They also spend a surprising amount of time giving second opinions to patients who have been offered surgery, or who flew abroad for unregulated stem cell infusions and now want to understand what they actually received.
The four broad types of regeneration in current clinical use
Biologists use “regeneration” to describe several different phenomena. In human medicine, when physicians talk about the “types of regeneration,” they usually mean categories of therapeutic strategy more than salamander‑style limb regrowth.
If you strip the jargon away, current clinical regenerative approaches fall roughly into four types of regeneration:
First, cell‑based therapies. These include stem cells and other progenitor or support cells derived from bone marrow, adipose tissue, birth tissues, or lab‑expanded lines. The goal is to provide living cells that can either differentiate into target tissue or, more realistically, secrete growth factors that nudge local tissue to repair itself.
Second, biologic scaffolds and matrices. These are structural materials, often derived from collagen or decellularized tissues, that give damaged tissue a framework on which to grow. Surgeons use them in rotator cuff repairs, hernia patches, and some cartilage procedures.
Third, growth factor and cytokine‑based approaches. Platelet‑rich plasma sits here, along with other blood‑derived products such as platelet‑rich fibrin. These treatments concentrate signaling molecules that orchestrate healing.
Fourth, gene and molecular therapies. This is the newest and least common in routine practice, but it includes treatments that modulate gene expression, use viral vectors, or alter specific molecular pathways to drive regeneration rather than degeneration. Much of this is still in trials, but it is already in use for a few rare diseases and is being studied aggressively in orthopedics and neurology.
When someone asks “What are the 4 types of regeneration?” in a clinical context, this is usually what we mean: cell therapy, scaffolds, growth factor biologics, and gene or molecular modulation. In day‑to‑day practice, PRP and cell‑based injections dominate.
What patients really want to know
Once we get past definitions, patients tend to circle the same core questions.
Is regenerative medicine painful?
Will insurance pay for regenerative medicine? What is the average cost of regenerative medicine, and what is the success rate of regenerative medicine for my specific problem? Who is a good candidate for regenerative medicine, and who should not bother?They also bring in stories. Joe Rogan talking about his stem cell treatment in Costa Rica. A neighbor who avoided knee replacement with PRP. An uncle who spent $10,000 on stem cells injected “everywhere” at a hotel conference room and felt nothing.
Sorting these stories into what is plausible, what is misleading, and what is outright fraudulent is a big part of the first visit.
Real‑world success rates: not one number, but several
There is no universal success rate for regenerative medicine. Asking that is a bit like asking, “What is the success rate of surgery?” Which surgery, for which diagnosis, in which patient?
That said, enough data have accumulated that we can speak in ranges for common conditions, and those ranges line up reasonably well with what clinicians see in practice.
Knee osteoarthritis
Knee arthritis is the most common reason people come in asking about PRP or stem cells. They hope to avoid or delay joint replacement.
For mild to moderate osteoarthritis, higher‑quality studies of PRP show that about 60 to 80 percent of patients report meaningful pain reduction and better function for 6 to 18 months. Some patients maintain benefit for several years, especially when they combine injections with weight loss, strength training, and activity modification.
Bone marrow concentrate and other stem cell‑type injections show promising but more heterogeneous results. In clinics, we often see roughly similar or slightly higher response rates than PRP in carefully selected patients, but the cost is significantly higher and the protocols vary widely. For advanced bone‑on‑bone arthritis, response rates fall; many of these patients eventually proceed to replacement despite temporary improvement.
Tendinopathies and sports injuries
For chronic tendinopathies such as tennis elbow, patellar tendon pain, or Achilles tendinosis, PRP has some of the best data in the regenerative toolbox.
In well‑selected cases that have failed standard rehab, many clinics see 70 to 85 percent of patients reach a meaningful improvement threshold, often with one or two injections. Improvement may take several weeks to months as the tendon remodels. Active patients who diligently follow an eccentric strengthening program tend to do best.
Acute sports injuries such as partial ligament tears and muscle strains show a more mixed picture. Some studies report faster return to play with PRP, especially in elite athletes whose training is optimized, but the general population data are not as impressive. In clinic, we see PRP as a useful option for certain high‑demand individuals, but not a magic accelerator for every sprain.
Spine and disc issues
This is where expectations often outrun evidence. Patients with chronic back pain want to know if stem cells or PRP can “regrow” a disc or erase years of degeneration.
There are encouraging early results for targeted PRP or cell‑based injections to facet joints or certain degenerative discs, but the data are still limited and protocols are far from standardized. Real‑world results show a subset of patients with clear benefit, another subset with mild or transient relief, and a meaningful proportion with no change at all.
Most experienced physicians present spine biologics as an option for carefully selected individuals after they have exhausted conservative therapy and before they consider surgery, not as a guaranteed alternative to fusion.
Aesthetic and dermatologic uses
Regenerative techniques have also migrated into aesthetics. PRP for hair loss, for example, often shows visible thickening in 50 to 70 percent of appropriately chosen patients, especially when started early in androgenic alopecia. Results for skin texture and scar remodeling can be good, but they are subtle compared with laser or surgical options and depend heavily on technique and adjunctive treatments.
Here too, real‑world success depends on matching the right modality to the right problem, not simply injecting PRP wherever someone is unhappy with aging.
The biggest problems and disadvantages of regenerative medicine
Patients often ask, “What is the biggest problem with regenerative medicine?” I usually give three, and none of them are a lack of promise.
The first problem is hype. Marketing frequently leaps far ahead of data. Clinics advertise “cures” for multiple sclerosis, autism, Parkinson’s disease, or generalized aging using intravenous stem cell infusions that have little to no robust evidence. This creates unrealistic expectations and makes it harder for responsible physicians to counsel patients honestly.
The second problem is variability and lack of standardization. Two products both labeled “stem cells” can be radically different in cell type, viability, and mechanism. Even PRP can vary in platelet concentration, white blood cell content, and activation method. That variability feeds into inconsistent clinical outcomes and makes it tricky to compare studies.
The third problem is access and cost. Most regenerative therapies are not covered by insurance, which prices out many patients who might benefit and, conversely, tempts others into overextending financially for treatments with uncertain payoff.
There are also more concrete disadvantages of regenerative medicine that patients feel directly. Procedures can involve real pain, particularly bone marrow harvests or injections into tight joint spaces. Many require downtime and rehab. Results are not guaranteed, and repeat treatments are sometimes needed.
When therapies are done irresponsibly, there is also risk of infection, tissue damage, or inappropriate delay of treatments that do have proven benefit, such as timely surgery for certain structural problems.
Is regenerative medicine painful?
Most biologic procedures sit on the same discomfort spectrum as standard orthopedic injections, with some important nuances.
PRP injections into superficial joints or tendons usually Regenerative Medicine Doctor involve a blood draw, processing time, then injection. Patients feel the needle stick, some pressure, and often a throbbing ache over the next 24 to 72 hours as the inflammatory phase kicks in. This is usually manageable with ice, rest, and non‑NSAID pain relievers such as acetaminophen.
Bone marrow concentrate procedures, particularly when marrow is aspirated from the iliac crest (pelvis), are more uncomfortable. These are typically done with local anesthesia, sometimes with light sedation. Patients describe sharp pressure during aspiration and a deep bruise‑like soreness afterward that can last several days.
Spine injections guided by fluoroscopy or CT can cause transient nerve irritation or soreness. Most clinics use detailed informed consent and pre‑procedure counseling so patients know what to expect. When done carefully, serious pain complications are rare, but it is not a spa treatment.
The key point: regenerative medicine is often briefly painful in service of a potential long‑term gain, not painless pampering. If a marketing brochure makes it sound like a quick, comfortable miracle with no downtime, be cautious.
Who is a good candidate for regenerative medicine?
Good candidates share certain patterns. They usually have a clearly defined problem that matches a therapy with at least some supportive evidence. They are willing to participate actively in rehab. And they understand that biologic treatments are a bet on probabilities, not certainty.
A short, practical way to think about candidacy looks like this:
The diagnosis is specific and imaging plus exam support it, such as focal cartilage loss, mild to moderate osteoarthritis, or well‑characterized tendinopathy. Conservative care has been attempted seriously, including targeted physical therapy, activity modification, and appropriate medications or injections. There is a logical regenerative mechanism, for example, trying PRP for a degenerative tendon rather than vague “whole‑body” injections for fatigue. The patient’s overall health supports healing, including decent nutrition, blood sugar control, and realistic activity goals. The decision fits the patient’s values, risk tolerance, and finances after a candid discussion of alternatives.By contrast, poor candidates include those with diffuse, poorly defined pain, severe deforming osteoarthritis that is clearly surgical, uncontrolled systemic disease, or expectations of complete cure from a single injection.
What regenerative medicine really costs
The moment we start talking money, faces get serious. Patients ask two linked questions: What is the average cost of regenerative medicine, and will insurance pay for regenerative medicine?
For most musculoskeletal uses in the United States, the answer is that insurance does not pay, or pays only for related imaging and evaluation, not the biologic product itself. Major private insurers and Medicare commonly label PRP, bone marrow concentrate, and commercial orthobiologic products as investigational, even when there is reasonable evidence in certain niches.
That means patients pay out of pocket for the actual treatment. Real‑world ranges vary by region, complexity, and provider expertise, but general ballparks per treatment episode look like this:
PRP injections: roughly 500 to 2,500 USD for a joint or tendon region, depending on whether a single or multi‑injection protocol is used and whether ultrasound guidance is included. Bone marrow concentrate or “stem cell” type joint injections: often 3,000 to 7,000 USD per major joint. Multi‑site or staged spine procedures using biologics: 4,000 to 10,000 USD or more, especially in private specialty centers. Aesthetic PRP, such as hair or facial treatments: typically 500 to 3,000 USD per session, with packages for multiple sessions.Prices outside the US vary widely. Some countries offer lower costs for similar quality, while others couple low prices with poor oversight and questionable product quality. Whenever you see a package price that seems “too good,” ask detailed questions about what is actually being injected and how cells or biologics are processed.
On the flip side, a minority of academic centers and integrated systems occasionally offer certain biologics, such as PRP for specific indications, at lower cost as part of protocols or internal pricing arrangements. Those slots are limited.
Regarding specific branded products, patients sometimes ask, Regenerative Medicine Doctor “Does insurance cover Kinetix?” Policies change, but as of the mid‑2020s, most insurers treat proprietary orthobiologic products the same way they treat generic PRP and stem cell procedures: as non‑covered, elective treatments. Anyone considering Kinetix or similar systems should confirm coverage directly with their insurer and the billing department before proceeding.
How much do regenerative medicine doctors make?
Income questions come up more often than you might expect, especially from trainees and medical students. They ask, “How much do regenerative medicine doctors make, and is this how physicians become the highest paid doctor specialty?”
Regenerative medicine is not a formal standalone specialty with its own salary data. A doctor’s income in this field largely tracks their base specialty and practice model.
An orthopedic surgeon who adds a high‑volume regenerative arm to a private practice may match or exceed upper‑tier orthopedic incomes, which can range above 600,000 USD annually in some markets. A PM&R or sports medicine physician running a modest biologics practice in an academic center might earn in the 250,000 to 400,000 USD range, anchored by institutional pay scales rather than cash‑based procedures.
When people ask “Who is the highest paid doctor specialty?” current surveys still point toward neurosurgery, orthopedic surgery, and some interventional cardiology and radiology roles, not regenerative medicine per se. Conversely, “What is the lowest paying doctor specialty?” often lands on pediatrics, family medicine, or preventive medicine, though there is variation by region.
Regenerative work can add revenue through elective cash‑pay procedures, but it also requires significant investment in equipment, staffing, regulatory compliance, and malpractice coverage. The physicians who do best financially are usually those who combine good medicine with a sound, transparent business model, not those who simply charge the highest prices for vague “stem cell packages.”
Does fasting for 72 hours regenerate cells?
There is growing public interest in fasting and longevity, and patients sometimes blend that with what they hear about stem cells. The question “Does fasting for 72 hours regenerate cells?” comes up more in the exam room than you might think.
Short answer: extended fasting appears to trigger beneficial processes such as autophagy and changes in immune cell populations in animal models and early human studies. A 72‑hour fast can lead to measurable shifts in metabolic pathways, markers of inflammation, and some immune cell dynamics.
However, calling that “cell regeneration” in the same sense as a targeted stem cell treatment is misleading. We do not yet have robust evidence that a 72‑hour fast leads to clinically meaningful tissue regeneration in humans, like regrowing cartilage or reversing tendon damage. For many patients, such long fasts can carry risks, especially with diabetes, cardiac disease, or frailty.
As physicians, we often support reasonable time‑restricted eating or shorter fasts as part of metabolic health when appropriate, while making clear that these strategies are not substitutes for targeted regenerative therapies or other needed medical care.
What country is best for stem cell treatment?
Many patients have heard about Joe Rogan’s stem cell experience in Costa Rica and ask, “Where did Joe Rogan get his stem cell treatment, and is that the best country for stem cells?”
Public reports and interviews describe him receiving high‑dose intravenous stem cell infusions in Costa Rica, a country known for relatively permissive regulations around certain biologic therapies compared with the US and Europe. Other popular destinations for stem cell tourism include Mexico, Panama, and some clinics in Eastern Europe and Asia.
The question “What country is best for stem cell treatment?” has no simple answer. It depends on the specific disease, the quality and oversight of the clinic, and whether the therapy is part of a legitimate clinical trial or unregulated cash‑pay offering.
Countries with stricter regulation, like the US, Canada, much of Western Europe, and parts of East Asia, tend to limit available treatments to those with at least some supporting evidence and quality control. This can mean fewer options, but also more safety and transparency. More permissive environments may offer experimental options sooner, but with higher risk of poor quality control, misleading marketing, and lack of recourse if something goes wrong.
From a physician’s standpoint, the safest approach is to favor centers that:
- Publish data, not just testimonials Operate under national regulatory oversight or credible academic frameworks Provide clear information on cell source, processing, dosing, and risks
Many legitimate trials for neurological, cardiac, and autoimmune indications run in highly regulated countries. For musculoskeletal and “wellness” indications, high‑end clinics abroad may tempt patients, but due diligence is crucial.
Where regenerative medicine fits in your overall treatment plan
When regenerative medicine works well, it can do two important things: help patients delay or avoid more invasive procedures, and improve quality of life in a measurable way. In knee osteoarthritis, for example, a 55‑year‑old physically active patient might gain several good years before needing a replacement. In persistent tendinopathy, a well‑timed PRP injection can move someone from chronic pain into sustainable performance.
The flip side is that regenerative medicine is not magic. It does not replace joint replacements when joints are structurally destroyed. It does not correct severe mechanical deformity. It will not overcome heavy smoking, unmanaged diabetes, morbid obesity, or a total lack of rehab effort.
For most patients, the smartest way to think about these treatments is as targeted, evidence‑informed tools that sit between conservative care and major surgery. They are worth considering when:
- The diagnosis is clear The mechanism of injury fits a biologic repair strategy Standard non‑operative care has been tried in good faith You understand costs, risks, and realistic odds of benefit
Ask your physician not only, “Can we do PRP or stem cells?” but, “What is the success rate of regenerative medicine for patients like me in your practice, and how will we measure whether it worked?” A thoughtful answer will not give you a single glossy percentage. It will give you ranges, caveats, and a plan. That nuance is what real‑world regenerative medicine looks like.